ArticlePharmacoEconomics - open2023

Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France.

Megane Caillon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.